Early premarket gappers
Gapping up: GEVA +126.4%, BRDR +104.3%, MGI +22.4%, LOCM +13.6%, PACB +12.3%, CYTX +5.6%, SDRL +4.7%, RTRX +4.3%, ALU +4.3%, NOK +4.2%, STM +3.8%, NBG +3.1%, YNDX +2.9%, ONCY +2.8%, PBR +2.6%, RIG +2.4%, ARMH +1.9%, ERIC +1.8%, SAN +1.4%, ASML +1.3%, HSBC +1.3%, DB +1.2%, CRM +1.1%, TRW +0.4%
Gapping down: ARDX -26.7%, WLT -12.8%, ATRS -4.3%, ALXN -3.9%, JBLU -3%, ANTM -2.1%, ACHC -1.7%, GFI -1.4%, SNY -1.3%, UAL -1%, DDD -0.9%, BHP -0.9%, DAL -0.8%, LUV -0.7%
Gapping down: ARDX -26.7%, WLT -12.8%, ATRS -4.3%, ALXN -3.9%, JBLU -3%, ANTM -2.1%, ACHC -1.7%, GFI -1.4%, SNY -1.3%, UAL -1%, DDD -0.9%, BHP -0.9%, DAL -0.8%, LUV -0.7%
---> US After Hours KOPN +16.7%, HLF +15.2%, EA +3.9%, ANAD -21.5%, ZU -18.4%, NDLS -17.9% following earnings/guidance..and also BRDR +102.7% (to be acquired by Pitney Bowes (PBI) for $14 per share in cash or ~$395 mln; co also reported earnings), MGI +37.1% (seeing reports that Western Union (WU) is in early talks to acquire the company), LOCM +13.6% (disclosed an amendment to Google Services Agreement; amendment provides for an extension of the agreement until March 31, 2018), PACB +12.4% (achieved second development milestone in clinical diagnostics agreement with Roche (RHHBY); $10 mln milestone payment brings total funding to date from RHHBY up to $55 mln)...ARDX -25.6% (announced results from its Phase 2a clinical trial evaluating Tenapanor in Chronic Kidney disease patients; trial did not meet the primary endpoint of decreasing the urinary albumin-creatinine ratio in treated patients), WLT -10.9% (discussed Going concern issues in 10-Q)